Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at NeoGenomics, Mainz Biomed, IsoPlexis, More

NeoGenomics: Dave Daly

NeoGenomics has appointed Dave Daly to its board of directors, effective Nov. 10. Daly is the president and chief operating officer of sequencing firm Singular Genomics and previously served as CEO at Thrive Earlier Detection, a company acquired by Exact Sciences earlier this year. He also worked at Illumina as SVP and general manager of commercial operations for the Americas, Foundation Medicine and Clarient as chief commercial officer, and Life Technologies, where he led the oncology business unit.

Daly also served in positions at Roche Diagnostics and Abbott.

Mainz Biomed: Heiner Dreismann

Heiner Dreismann has been appointed to the strategic advisory board of cancer molecular diagnostics company Mainz Biomed. He is the former president and CEO of Roche Molecular Systems and held other senior positions at Roche, including head of global business development for Roche Diagnostics and member of Roche's global diagnostic executive committee.

IsoPlexis: Michelle Reid, Anthony Catalano

IsoPlexis has appointed Michelle Reid as VP of service and support and Anthony Catalano as senior VP of operations. Reid previously served as senior director of customer service and support at PGDx, and prior to that worked in customer support for Qiagen. She holds a Ph.D. in molecular biology from LaTrobe University in Australia. Catalano previously spent 11 years as senior director of operations at PerkinElmer. He also previously served as senior director of manufacturing operations at VisEn Medical from 2001 until its acquisition by PerkinElmer in 2010. Catalano holds an M.S. in chemistry from Brandeis University.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.